Success Metrics

Clinical Success Rate

88.9%

Based on 8 completed trials

Completion Rate

89%(8/9)

Active Trials

1(8%)

Results Posted

13%(1 trials)

Terminated

1(8%)

Phase Distribution

Ph not_applicable

31%

Ph phase_2

15%

Ph phase_4

Ph phase_1

38%

Ph phase_3

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution13 total trials

Phase 1Safety & dosage

5(38.5%)

Phase 2Efficacy & side effects

2(15.4%)

Phase 3Large-scale testing

1(7.7%)

Phase 4Post-market surveillance

1(7.7%)

N/ANon-phased studies

4(30.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

8 of 10 finished

Non-Completion Rate

20.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(8)

Terminated(2)

Other(1)

Detailed Status

Completed8

Active, not recruiting1

unknown1

Terminated1

Not yet recruiting1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

88.9%

Most Advanced

Phase 4

Trials by Phase

Phase 15 (38.5%)

Phase 22 (15.4%)

Phase 31 (7.7%)

Phase 41 (7.7%)

N/A4 (30.8%)

Trials by Status

active_not_recruiting18%

unknown18%

completed862%

terminated18%

not_yet_recruiting18%

withdrawn18%

Recent Activity

1 active trials

Showing 5 of 13

not_yet_recruitingnot_applicable

6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province

NCT07198685

active_not_recruitingphase_3

Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort

NCT06081361

completednot_applicable

Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS

NCT04717908

completedphase_2

Repeated iTBS Cycloserine Motor Plasticity

NCT05081986

unknownphase_4

A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China

NCT05306223

View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials

NCT07198685Not Applicable

6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province

Not Yet Recruiting

NCT06081361Phase 3

Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort

Active Not Recruiting

NCT04717908Not Applicable

Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS

Completed

NCT05081986Phase 2

Repeated iTBS Cycloserine Motor Plasticity

Completed

NCT05306223Phase 4

A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China

Unknown

NCT03511599Phase 1

Cycloserine rTMS Plasticity Augmentation in Depression

Completed

NCT00000796Not Applicable

A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.

Completed

NCT02735694Phase 1

Cycloserine in the Treatment of Sleep Apnea

Terminated

NCT03432689Phase 1

Cycloserine rTMS Plasticity Augmentation

Completed

NCT00000194Phase 2

Neurobiology of Opioid Dependence: 3 - 3

Withdrawn

NCT01062932Phase 1

Investigation of Cycloserine as a Smoking Cessation Treatment